INTOCELL
Intocell is a biotechnology company that develops antibody drug conjugate (ADC) platform technologies.
INTOCELL
Industry:
Biotechnology Information Technology Medical
Founded:
2015-01-01
Address:
Daejeon, Taejon-jikhalsi, South Korea
Country:
South Korea
Website Url:
http://www.intocell.co.kr
Total Employee:
11+
Status:
Active
Total Funding:
1000 M KRW
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Font Awesome Nginx Euro Google Maps PHP PHP 7
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Current Employees Featured
Founder
Investors List
Stonebridge Capital
Stonebridge Capital investment in Series A - Intocell
Official Site Inspections
http://www.intocell.co.kr
- Host name: 121.254.178.235
- IP address: 121.254.178.235
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Intocell" on Search Engine
Intocell - Crunchbase Company Profile & Funding
Founded Date 2015. Founders Park Tae-gyo. Operating Status Active. Last Funding Type Series C. Also Known As 인투셀. Company Type For Profit. Intocell is a biotechnology …See details»
IntoCell Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for IntoCell. Use the PitchBook Platform to explore the full profile.See details»
WuXi CRDMO spinoff WuXi XDC partners with IntoCell
Jan 3, 2024 WuXi XDC, which spun off from WuXi Bio And WuXi STA in November, has forged a partnership with the South Korean biotech IntoCell. As part of the pact, IntoCell …See details»
IntoCell Company Profile - Craft
IntoCell is a company that develops and commercializes conjugate platform technologies, comprised of scaffold moiety, ligands, toxins, linkers, and conjugation methods. It aims …See details»
WuXi XDC Enters into Partnership Agreement with IntoCell, …
SHANGHAI, Jan 3, 2024—WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of …See details»
WuXi XDC Enters into Partnership Agreement with IntoCell, …
Jan 3, 2024 WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of …See details»
IntoCell and Ab Studio to Start Research Collaboration - PR …
Oct 14, 2021 DAEJEON, South Korea, and HAYWARD, Calif., Oct. 14, 2021 /PRNewswire/ -- IntoCell, a South Korean biotech developing novel antibody drug conjugate (ADC) …See details»
IntoCell Enters into Development and License Option Agreement …
Jan 5, 2023 Under the agreement, IntoCell, a South Korean biotech developing novel antibody drug conjugate (ADC) platform technologies, will provide proprietary drug …See details»
Intocell - Funding, Financials, Valuation & Investors - Crunchbase
Funding. Intocell has raised a total of. ₩35B. in funding over 2 rounds. Their latest funding was raised on Jan 4, 2021 from a Series C round. Intocell is funded by 10 investors. …See details»
WuXi XDC Enters into Partnership Agreement with IntoCell, …
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the …See details»
IntoCell Enters into Development and License Option
Jan 5, 2023 Under the agreement, IntoCell, a South Korean biotech developing novel antibody drug conjugate (ADC) platform technologies, will provide proprietary drug …See details»
WuXi XDC Enters into Partnership Agreement with IntoCell, …
SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the …See details»
PharmaVentures advises IntoCell on its Research Collaboration …
Oct 15, 2021 About IntoCell, the OHPAS linker and PMT technology. IntoCell has developed a state-of-the-art linker technology comprising of a novel self-immolative …See details»
Intocell
IntoCell, Into Global Biotech. IntoCell, Into Global Biotech. Core Technology 01 OHPAS TM LINKER. Core Technology 02 OHPAS TM LINKER-TOXIN LIBRARY. RESEARCH & …See details»
WuXi XDC Enters Into Partnership Agreement With IntoCell, …
Jan 2, 2024 Shanghai /PRNewswire/ - WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the …See details»
Intocell - Contacts, Employees, Board Members, Advisors & Alumni
Start Your Free Trial. Intocell is a biotechnology company that develops antibody drug conjugate (ADC) platform technologies.See details»
WuXi XDC Enters into Partnership Agreement with IntoCell, …
SHANGHAI, Jan. 3, 2024 /PRNewswire/ — WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the …See details»
WuXi XDC Enters into Partnership Agreement with IntoCell, …
SHANGHAI, Jan. 2, 2024 /PRNewswire/ — WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the …See details»
WuXi XDC and IntoCell Establish Collaboration to Hasten ADC …
Jan 3, 2024 WuXi XDC, a prominent global CRDMO specializing in Antibody-Drug Conjugates (ADC) and other bioconjugates, will be collaborating with IntoCell, a Korean …See details»
2.12: Organization of Cells - Biology LibreTexts
The body of a multicellular organism, such as a tree or a cat, exhibits organization at several levels: tissues, organs, and organ systems. Similar cells are grouped into …See details»